Allergy Therapeutics reports accelerated revenue growth in its second half

Health Pharma & Biotech Written by: Jamie Ashcroft 07:49 Wed 29 Jul 2026 --> Proactive has a commercial relationship with Allergy Therapeutics PLC. This article was produced independently under Proactive's Editorial Standards Policy . Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Jamie Ashcroft Jamie Ashcroft, the News Editor for Proactive UK, has developed an impressive career in financial journalism, focusing on the small-cap sector for over fourteen years. Before joining the Proactive team, he was a stockbroker during the global financial crisis, a role that complemented his educational background - a first-class degree in Business and Economics and qualifications in software design and development. As one of the early external hires at Proactive in 2009, Jamie contributed... Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Allergy Therapeutics PLC ( AIM:AGY OTC:AGYTF ) View Price & Profile Allergy Therapeutics reports accelerated revenue growth in its second half Published: 07:49 29 Jul 2026 BST Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) told investors that revenue growth accelerated in its second half and has guided for a further step-up in the current year as Grassmuno enters its first full peak treatment season. Second-half revenue is expected to reach £23.6 million, up more than 12% on a reported basis from £21 million a year earlier. That compares with 7% growth in the first half. Full-year revenue is forecast at £59.9 million, 9% higher than the previous year’s £55 million. Constant-currency growth was around 5%, including increases of more than 4% in Germany and 12% in Spain. The allergy immunotherapy specialist expects double-digit revenue growth in the year to June 2027, supported by Grassmuno’s first full high season and the end of Germany’s transition away from unregistered products under the TAV programme. Cash stood at £24.2 million at the year-end, compared with £12.8 million a year earlier, after the company repaid its shareholder loans and drew down a new £40 million secured facility from Hayfin. Continue reading